BioMendics, LLC, a clinical-stage biotechnology company developing innovative therapies for rare genetic skin disorders, ...

Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has ...

"With a Phase 2a asset in HSV and an EBV program approaching clinical readiness, Innovative Molecules is uniquely positioned as a leading developer of next-generation therapies targeting herpesviruses ...

The novel topical gel, designed to clear mutant keratin aggregates and restore intermediate filament network integrity via autophagy, is undergoing evaluation in the phase 2 TAMES-02 trial.

BioMendics, LLC, a clinical-stage biotechnology company developing innovative therapies for rare genetic skin disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of ...

Federal prosecutors have charged two more individuals as co-conspirators in a thwarted multi-state plot to launch an alleged ...

SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced ...

Ships NV-387 Drug Supply To DRC For Phase II Mpox Trial. NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo in preparation ...

Federal prosecutors have charged a Missouri man as the sixth co-conspirator in a thwarted multi-state plot to launch an ...

A study published in Nature Physics provides new molecular-level evidence from simulations that liquid water is not a single uniform substance, but a constantly shifting mixture of two distinct ...

Five months after Corxel Pharmaceuticals reeled in hundreds of millions of dollars to support further development of its oral ...